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g.2012.0Abstract Hepatocellular Carcinoma is a multifactorial, multistep and complex process. Its prog-
nosis is poor and early diagnosis and monitoring of metastasis of HCC is of utmost importance.
Circulating alpha-fetoprotien mRNA has been proposed as a marker of HCC cells disseminated
into the circulation but the speciﬁcity of this molecular marker and its correlation with the main
HCC clinico-pathological parameters remain controversial. In recent years; several different
multi-marker assays have been developed for the detection of hepatoma cells in the peripheral blood
of patients with HCC.
In this study 58 patients and 15 matched healthy volunteers were included; the patients were
divided into three groups; group A: patients with primary HCC (n= 32), group B: patients with
cirrhosis with no evidence of HCC (n= 12), group C: patients with metastatic cancer in liver
(n= 14). Group D: 15 healthy volunteers age and sex matched. The staging of HCC was carried
out according to the Tumor/Node/Metastasis (TNM) classiﬁcation.
Peripheral blood samples were obtained from all subjects; MAGE-1 and MAGE-3 and AFP
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22 S.H. Teama et al.The positive rates of MAGE-1, MAGE-3 and AFP mRNAs were 18/32 (56.3%), 15/32 (46.9%)
and 19/32 (59.4%) respectively in the primary HCC patients.
In the cirrhotic group only 4/12 (33.3%) patients were positive for AFP mRNA, whereas in the
metastatic group 5/14 (35.7%) and 4/14 (28.6%) were positive to MAGE-1 and MAGE-3 mRNAs
respectively. MAGE-1 and MAGE-3 mRNAs were correlated with TNM clinical stages; tumor
number and tumor size (p< 0.05).
Our results indicate that a multi-marker nested RT-PCR assay with cancer-speciﬁc markers such
as MAGE-1 and MAGE-3 in combination with a hepatocyte-speciﬁc AFP marker may be a prom-
ising diagnostic tool for monitoring hepatocellular carcinoma patients. Nested PCR exhibits higher
sensitivity, stronger speciﬁcity and lower false-positive occurrence as compared to single RT.
 2012 Ain Shams University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Hepatocellular carcinoma (HCC) is one of the most common
malignant diseases in the world. Approximately, 560,000 new
cases of HCC are diagnosed each year, constituting 6% of
all new human cancers [1]. Hepatoma tissues can synthesize
many tumor-related proteins, polypeptides and isoenzymes.
Hepatoma cell circulating speciﬁc biomarkers are useful pre-
dictors for early diagnosis of HCC or monitoring metastasis
or post operative recurrence of disease [2,3].
Alpha Fetoprotein is a 70 kDa glycoprotein that in hu-
mans is encoded by the AFP gene. AFP is produced by
the yolk sac and the liver during fetal life [4,5]. Human
a-Fetoprotein is a well-known marker for hepatoma cells.
Although the serum AFP level could be one of the useful
biochemical markers for the diagnosis of HCC, it is not so
sensitive. Recently; AFP gene transcripts have been used as
targets of the RT-PCR assay in blood from HCC patients
but the detection of these gene transcripts do not truly reﬂect
the presence of tumor cells, since non-tumors liver cells also
abundantly express AFP mRNA, which could be released
into blood because of hepatitis, liver cirrhosis and surgical
injuries [6].
Since cancer cells are usually very heterogeneous, different
cancers express different markers and even cells from the
same tumor may not be identical. Thus, single-marker RT-
PCR has its limitations in sensitivity and speciﬁcity [7,8].
The melanoma antigen gene family (MAGE) consists of
groups of genes: MAGE-A, B and C. . . These are all localized on
theXchromosomeat locationsXq28,Xp21.3, andXq26, respec-
tively. MAGE-A comprises 12 genes (MAGE-1–MAGE-12).
The products of the MAGE family are highly speciﬁc to cancer
cells; thus, they have been extensively studied as important
tumor markers for cancer prognosis and immunotherapy. The
members of MAGE gene family are highly expressed in
humanHCC.MAGE-1 and 3 are among these tumor associated
antigens that play an extremely important role in tumor
growth by rendering high, tumor cell metabolic rate. They
encode 46 and 44 kDa proteins, respectively and are expressed
in a very limited range of normal tissues (germcells andplacenta)
[9,10].
This study was conducted to examine the expression of
MAGE-1 and MAGE-3 and AFP gene transcripts in blood
specimens obtained from patients with primary HCC and
also from HCC-free controls to assess a multi-marker nested
RT-PCR assay for the detection of circulating HCC cells and
may suggest a diagnostic capability for these markers.2. Subjects and methods
2.1. Subjects
This study had been carried out at Internal Medicine Depart-
ment; Ain Shams Hospital; it included 58 patients and 15
healthy volunteers as a control. All subjects provided their in-
formed consent to participate in the study. The patients were
divided into three groups: Group A; patients with primary
HCC (n= 32) at variable stages of the disease (proven histop-
athologically), 18 males and 14 females. Group B; patients
with cirrhosis (n= 12), 7 patients on top of HBV and 5 pa-
tients on top of HCV with no evidence of HCC (proven radio-
logically), 7 males and 5 females. Group C; patients with
metastatic cancer in the liver (n= 14), 9 males and 5 females.
Group D; 15 healthy volunteers’ age and sex matched, proved
clinically and by laboratory investigations to be free from dis-
eases. Brief information on each group is given in (Table 1).
Each patient was subjected to full history taking, complete
general and abdominal examination, imaging investigation
(abdominal ultrasonography and C.T) and laboratory evalua-
tion; analysis of liver functions, including: total bilirubin, Ala-
nine Transaminase (ALT), Aspartate Transaminase (AST),
serum albumin and prothrombin time, viral hepatitis markers,
including HCV antibody, HBV surface antigen and antibody,
HBV core antibody.
Ultrasound guided liver biopsy with written consent was
done for group A patients to conﬁrm the diagnosis of HCC
by histopathology. The procedure was done by semi-
automated true cut needle under local anesthesia (xylocaine).
Platelet count above 50,000 and prothrombin time not more
than three seconds above normal were mandatory before the
procedure. Patients were kept at the hospital 6 h after the
procedure for observation of vital data and occurrence of
any complications.
According to radiological ﬁndings and Tumor/Node/
Metastasis classiﬁcation, the HCC patients were divided into:
Stage I: 6 patients (18.8%), stage II: 7 patients (21.9%), stage
III: patients 10 (31.2%) and stage IV: 9 patients (28.1%).2.2. Methods
2.2.1. Blood samples
Fifteen ml of whole blood was withdrawn from the peripheral
veins from both patients and healthy volunteers and were
collected into two tubes: 10 ml of heparinized blood for
Table 1 Demographic information of enrolled groups.
Healthy volunteer HCC Cirrhosis Metastatic cancer F* P
n 15 32 12 14
Gender
Male 10 (66.7%) 18 (56.2%) 7(58.3%) 9 (64.3%)
Female 5 (33.3%) 14 (43.8%) 5 (41.7%) 5 (35.7%)
Age
Mean ± SD 55.73 ± 9.1 56.62 ± 8.42 58.10 ± 7.50 60.28 ± 6.83
(39–72) (41–69) (47–70) (51–71) 0.92 p> 0.05
* ANOVA test.
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tubes for separation of serum to detect AFP.
2.2.2. I. Isolation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) were isolated
from blood by density gradient centrifugation using Ficoll-
hypaque 1077 (Sigma, USA) at 1200 g for 30 min at 4 C.
The interface cells were removed, washed twice with 25 ml of
sterile PBS (pH7.3), pelleted, and resuspended in 1 ml of
PBS. The cells were pelleted again at 1200 g for 2 minutes.
The cell pellets were kept at 80 C until RNA extraction.
2.2.3. II. Extraction of total RNA from nuclear cells
Total RNA of nuclear cells was extracted using RNA extrac-
tion kit (Qiagen) according to the manufacturer’s instruction.
All RNA preparation and handling steps took place in a bio-
safety level 2 laminar ﬂow hood, under RNAse-free condi-
tions. The isolated RNA was resuspended in RNAse-free
water and stored at 80 C until assay. The RNA concentra-
tion was assessed by absorbance reading at 260 nm with UV
spectrophotometry (Beckman; Du series 650, INC, USA). As
positive controls, RNA samples were also prepared from the
human tumor cell line HepG2 prepared by cell culture unit
in a medical research center; Ain Shams University.
2.2.4. III. Ampliﬁcation by nested reverse transcriptase
polymerase chain reaction (RT-PCR)
Three different PCR reactions were performed with each sam-
ple in order to amplify fragments of MAGE-1 and MAGE-3
and AFP mRNAs.
2.3. Reverse transcription (Complementary cDNA synthesis)
Reverse transcription reaction was carried out in a 20 ll reac-
tion mixture by using ﬁrst strand cDNA synthesis kit (Prome-
ga; USA) according to manufacture’s instruction.
2.4. Nested PCR for MAGE-1 and 3 mRNAs and AFP mRNA
A total amount of 50ll reaction solution contained 5 ll 10X
PCR buffer, 0.2 mmol/L of each dNTPs, 30 pmol of each
external primers, 2.5U Taq DNA polymerase (Promega;
USA) and cDNA. Thermocycling in either an MJ Research
PTC 200 (MJ Research, Inc., Boston, Mass.) or Perkin-Elmer
9600 (Perkin-Elmer, Cambridge, United Kingdom) according
to the following cycle proﬁle using different primers for
MAGE-1 and MAGE-3 and AFP (Table 2) for MAGE-1;denaturation at 94 C for 6 min, annealing at 60 C for 30 s
and extension at 72 C for2 min for the ﬁrst cycle followed
by (denaturation 94 C for 40 s, annealing 60 C for 30 s and
extension 72 C for 30 s) thermal cycles were repeated 35 times;
terminal extension at 72 C for 2 min. For AFP; initial dena-
turation at 94 C for 2 min followed by the following sequence:
(94 C for 1.5 min., 57 C for 1.5 min. and 72 C for 2.5 min)
plus a terminal extension at 72 C for 10 min.; thermal cycles
were repeated 35 times and for MAGE-3 denaturation at
94 C for 4 min. Followed by (94 C for 45 s and 72 C for
3 min) for 35 cycles; terminal extension at 72 C for 2 min.
A sample of 10 ll of the ﬁrst ampliﬁcation product was fur-
ther ampliﬁed using the inner pair of the primer. PCR proce-
dure was; (94 C for 45 s, 58 C for 45 s, and 72 C for 45 s)
for MAGE-1 and (94 C for 40 s, 58 C for 30 s, and 72 C
for 30 s) for AFP and (94 C for 45 s, 69 C for 45 s, and
72 C for 45 s) for MAGE3; the thermal cycles were repeated
32 times as well as followed by ﬁnal extension at 72 C for
2 min.
To verify the successful preparation of mRNA, samples
were detected for the presence of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) mRNA.
Reaction tubes containing cDNA from Hep G2 cells as po-
sitive controls and no template control sample without cDNA
addition were included as negative controls for each PCR
reaction.
2.4.1. Immunoassay for detection of AFP
For the analysis of AFP; we used a commercially available kit.
The assay was performed according to the manufacturer’s rec-
ommendation using Elecsys 2010 (roche Diagnostics Gmbh,
D-68298 Mannheim).
2.4.2. Gel electrophoresis
The ﬁnal ampliﬁcation product was electrophoresed on 2%
agarose gel and stained with ethidium bromide for the speciﬁc
band of bp.2.5. Statistical analysis
The results were analyzed using the Statistical Package of So-
cial Sciences (SPSS) computer software program, version 16.0
(Chicago, IL, USA). Quantitative data were presented as
mean ± SD for normally distributed data and as medians
and percentiles for skewed data. Qualitative data were pre-
sented in the form of frequencies and percentages. For nor-
mally distributed parameters, differences among groups were
Table 2 Sequences of oligonucleotide primers used for PCR reaction [7,11,12].











MAGE-3 primer11 TGG AGG ACC AGA GGCCCC C 725
Outer-sense GGA CGA TTA TCA GGAGGC CTG C
Outer-antisense CGG AGG AGC ACT GAAGGA GAA G 371
Inner-sense CCT CCT CTT CTT GGTTGC TGG
Inner-antisense
GAPDH primer12
Sense CTA CTG GCG CTG CCA AGG CTG T 390
Anti sense GCC ATG AGG TCC ACC ACC CTG T
1          2       3      4       5       6       7      8 
143 BP 
24 S.H. Teama et al.tested by one-way analysis of variance (ANOVA). For
Qualitative data, differences among groups were tested using
Pearson’s chi-square test (X2) and Fisher’s exact test. A p value
less than 0.05 was considered statistically signiﬁcant.
2.6. Results
2.6.1. Interpretation of the results
According to the design of primer pairs, the PCR products of
(149 and 143); (725 and 371) and (176 and 101) base pairs were
ampliﬁed from MAGE-1 and MAGE-3 and AFP cDNA
respectively (Figs. 1–3); while GAPDH band ampliﬁcation
was visualized corresponding to 390 bp. The sizes of PCR        1         2        3       4        5       6         7       8 
100 BP 
Figure 1 Representative pictures: Electrophoretic separation of
PCR ampliﬁed product; detection of gene transcripts in blood
specimens from HCC patients: Lane 1: DNA molecular size
marker, Lane 2: Positive control, Lane 3: Negative control, Lane
4&5: Cases showing AFP positive gene transcript, Lane 6:
Negative case.
100 BP 
Figure 2 Representative pictures: Electrophoretic separation of
PCR ampliﬁed product; Detection of gene transcripts in blood
specimens from HCC patients: Lane 1: DNA molecular size
marker, Lane 2: Positive control, Lane 3: Negative control, Lanes
4 and 5: Cases showing MAGE1 positive gene transcript, Lane 6:
Negative case, Lane 7: Negative case.products were estimated by comparison with DNA molecular
mass markers (Bio-Rad; EZ Load).
Expression of MAGE-1, MAGE-3 and AFPmRNAs in
peripheral blood in patients and controls (Fig. 4).
MAGE-1 and MAGE-3 mRNAs were detected in 18/32
(56.3%), 15/32 (46.9%) in primary HCC patients and none of
the cirrhotic group patients expresses MAGE-1 and MAGE-3
mRNAs 0/12 (0%); and 5/14 (35.7%); 4/14 (28.6%) in patients
with metastatic cancer in the liver. The positive rate for
MAGE-1 and MAGE-3 mRNAs in blood was higher in pri-
mary HCC patients; compared to metastatic group. Neither
of the normal healthy volunteers and cirrhotic group gave
detectable signals for MAGE-1 and MAGE-3 mRNAs.
The frequencies of the positive rate MAGE-1 and MAGE-
3mRNAs in blood were associated with the progression of
HCC as indicated by clinical parameters such as TNM tumor
stage, the positive rate MAGE-1 and MAGE-3mRNAs in
       1          2          3          4          5         6 
300 BP 
Figure 3 Representative pictures: Electrophoretic separation of
PCR ampliﬁed product; Detection of gene transcripts in blood
specimens from HCC patients: Lane 1: DNA molecular size
marker, Lane 2: Positive control, Lane 3: Negative control, Lanes
4 and 5: Cases showing MAGE3 positive gene transcript, Lane 6:
Negative case.
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(p< 0.05) (Table 3) and also the positive rate was correlated
with tumor number and tumor size (p< 0.05) (Table 4), These
results indicate that the incidence of the expression of cancer
speciﬁc molecular markers MAGE-1 and MAGE-3mRNAs in-
creased in advanced stages of disease and correlatedwith clinical
severity.
Concerning AFPmRNA, it was positive in 19/32(59.4%) in
primary HCC patients compared to metastatic cancer in liver
group 0/14 (0%); 4/12 (33.3%) in patients with cirrhosis of
the liver. The positive rate for AFPmRNA in blood was signif-




Specificity of MAGE-1 and 3 mRNA and
MAGE-1 56.30% 0% 35
MAGE-3 46.90% 0% 28
AFP 59.40% 33.30% 0
HCC Cirrhosis Met
Figure 4 Expression of MAGE-1; MAGE-3 m




MAGE-1 mRNA 0 (0%) 2 (28.6%)
MAGE-3 mRNA 0 (0%) 3 (42.9%)
AFP mRNA 0 (0%) 4 (57.1%)
* Comparison between TNM I–II and TNM III–IV (Sig. p< 0.05).chronic liver disease (p< 0.05). Neither of the normal healthy
volunteers and metastatic groups showed detectable signals for
AFP mRNA.
The correlation of AFPmRNA molecular marker with the
main clinico-pathological parameters remains unclear; the fre-
quency of positive cases of AFPmRNA in TNM stages III–IV
was signiﬁcantly higher than in stages I–II but no correlation
was found between tumor size or tumor number and the posi-
tive rate of AFPmRNA (Tables 3 and 4).
The detection of MAGE-1mRNA in peripheral blood is
correlated with that of AFPmRNA and MAGE-3mRNA
and the detectable rate of MAGE-1 mRNA in AFPmRNA po-
sitive patients was signiﬁcantly different from that in AFPmR-
NA negative patients (p< 0.05). Also the detectable rate of
MAGE-3 mRNA in AFPmRNA positive patients was signiﬁ-
cantly different from that in AFPmRNA negative patients
(p< 0.05) (Table 5).
Concerning AFP in different groups (Table 6); in this work,
AFP was evaluated at a cut off value of 400 ng/ll (0.400 IU/
ml) although HCC patients with a high level of serum AFP
exhibited detectable concentrations of MAGE-1and 3 mRNAs
and AFPmRNA more often than those with a low serum AFP
level, there is no signiﬁcant difference (Table 7).
Concerning multimarker expression of MAGE1 and
MAGE3 and AFP mRNAs; the result indicates that 24/32
(75%) were positive for at least one marker and 10/32
(31.3%) positive for the three molecular markers which
strongly indicate hamatogenous spread.
3. Discussion
HCC is the ﬁfth most common cancer worldwide and repre-








RNAs and AFPmRNA in different group.
imary HCC patients group in relation to TMN staging.
*
III IV x2 P
10 9
7 (70%) 9 (100%) 14.0 0.001
4 (40%) 8 (88.9%) 5.0 0.03
6 (60%) 9 (100%) 4.8 0.04
Table 4 Expression of MAGE-1, MAGE-3 and AFP mRNAs in primary HCC patients in relation to Gender, tumor number and
size.
n MAGE-1 p* MAGE-3 p* AFP p*
Gender
Male 18 8 (44.4%) 7 (38.9%) 10 (55.6%)
Female 14 10 (71.4%) 0.16 8 (57.1%) 0.47 9 (64.3%) 0.72
Number of nodules
Solitary 13 2 (15.4%) 3 (23.07%) 5 (38.46%)
Multiple 19 16 (84.2%) 0.001 12 (63.16%) 0.03 14 (73.68%) 0.07
Tumor size
<5 11 3 (27.27%) 2 (18.18%) 4 (36.36%)
>5 21 15 (71.43%) 0.02 13 (61.90%) 0.02 15 (71.42%) 0.06
* Chi square test or Fisher’s exact test for small sample size (Sig. p< 0.05).
Table 5 Comparison of expression of marker genes in blood samples of primary HCC patients.
AFP MAGE3
n Negative Positive p* Negative Positive p*
MAGE1
Negative 14 9 5 11 3
Positive 18 4 14 0.02 6 12 0.01
Total 32 13 19 17 15
* Chi square test (Sig. p< 0.05).
Table 6 Serum AFP level in different group.
Serum AFP (ng/ll) Healthy volunteer HCC Cirrhosis Metastatic p
Mean ± SD 4.86 ± 3.39 768 ± 570 78.3 ± 33.6 426 ± 241
Median 5.0 510 81.5 436
Minimum – 123 34 125 p< 0.05
Maximum 9 2225 145 980
Range 9 2132 111 855
Table 7 Expression of MAGE-1 and 3 mRNAs and AFP
mRNA and serum AFP level in primary HCC patients.
Serum AFP X2* p
<400 >400
n 13 19
MAGE-1 mRNA 5 (38.5%) 13 (68.4%) 2.80 0.09
MAGE-3 mRNA 4 (30.8%) 11 (57.9%) 2.28 0.13
AFP mRNA 7 (53.8%) 12 (63.2%) 0.22 0.50
* Chi square test (Sig. p< 0.05).
26 S.H. Teama et al.cancers. The disease severely affects the Egyptian population.
HCC is a high-grade malignancy showing a rapid inﬁltrating
growth, early stage metastasis, poor therapeutic response and
disappointing prognosis even after successful curative resec-
tion surgery [13]. The early dissemination of cancer cells to sec-
ondary sites is the main cause of mortality of patients with
solid tumors [14].
The routine diagnosis of HCC has been largely dependent
on the serological levels of AFP. However, its clinical applica-
tion has been lost signiﬁcantly due to the fact that liver diseases
other than HCC are accompanied by high levels of AFP. Inaddition, a signiﬁcant proportion of HCC patients did not
have an elevated AFP.
False positive results will be unavoidable if qualitative AFP
mRNA determination is used as the single marker for the
detection of circulating cancer cells. Subsequently, AFP repre-
sents liver cell-speciﬁc, not tumor speciﬁc markers [3,14]. Using
a multi-marker assay combining cancer speciﬁc markers and li-
ver speciﬁc marker may improve the methods of screening of
HCC.
The purpose of this study was to detect circulating HCC
cells in blood samples using tumor speciﬁc markers, MAGE-
1, MAGE-3mRNAs and liver speciﬁc marker AFPmRNA by
nested PCR which provides 100 fold sensitivities. Moreover,
nested RT-PCR has increased the speciﬁcity owing to the use
of two pairs of speciﬁc primers.
In this study, the positive rate of MAGE-1, MAGE-3 and
AFPmRNAs was 56.3%, 46.9% and 59.4% respectively in pri-
mary HCC patients, 100%; 88.9% and 100% in HCC patients
with extrahepatic metastasis. In 24/32 (75%) patients, there is
at least one positive marker. 10/32 (31.3%) patients were posi-
tive for the three markers which strongly indicate the presence
of malignant hepatocytes in the circulatory system. In contrast,
none of the healthy clinical control samples show detectable
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peripheral blood.
Our results indicated that MAGE-1 and MAGE-3 mRNAs
are cancer speciﬁc, and could be detected in samples from pa-
tients with both primary and metastatic cancers in liver and the
detection of AFPmRNA in peripheral blood is associated not
only with primary hepatocellular carcinoma but also with cir-
rhosis. AFPmRNA represents a liver speciﬁc marker not a tu-
mor speciﬁc marker and AFP transcript is valuable in the
diagnosis of HCC but not a speciﬁc marker to the diagnosis
of HCC; thus cancer-speciﬁc MAGE-1 and MAGE-3 genes
are a powerful complement to the hepatocyte speciﬁc AFP
gene for the detection of circulating HCC cells.
Recently, several different multimarker assays have been
developed for the detection of tumor cells in the peripheral
blood of patients with variable malignancies. Several reports
[15] [16] have revealed that; MAGE gene transcripts were
highly expressed in HCC tissues even in alpha fetoprotein neg-
ative HCC, but not in non-tumor liver tissues.
MAGE gene transcripts have been regarded as tumor spe-
ciﬁc markers and found to be highly expressed in a variety
of histological types of cancer; the positive rate was 46–80%
of MAGE-1 transcript and 42–68% of MAGE-3 transcript
in HCC samples. A proportion of 74–86% of HCC tissue sam-
ples were positive for at least one MAGE gene transcript, while
no expression of MAGE transcript was detected in surround-
ing non-cancerous tissues, nor in liver cirrhosis [17–19].
Miyamoto et al. [8] reported that MAGE-1, MAGE-3 and
AFP transcripts were detected in 9 (12.7%), 3(4.8%), and
10(15.9%) of 71 blood specimens from HCC patients, respec-
tively. In contrast, MAGE-1mRNA and AFPmRNA were de-
tected in 27(41.5%) and 35(53.8%) of 65 blood samples from
the HCC patients respectively as reported by Yang et al. [9]
which agree with our study. The difference in result is due to
the method used; nested RT-PCR.
Zhao et al. investigated MAGE-1 gene expression in
HCC, cirrhosis and normal liver tissues. They found that
MAGE-1 was detectable in 72.2% of HCC samples, while
none of the cirrhotic or normal liver tissues expressed this
mRNA [20].
Zhang et al. reported that, in 86 tumor specimens, the pos-
itivity for MAGE-1, MAGE-3, and AFP genes was 34.9% (30/
86), 60.5% (52/86) and 69.8%(60/86) respectively, and all spec-
imens expressed at least one marker. MAGE-1, MAGE-3, and
AFP transcripts were detected in 12 (14.0%), 18 (20.1%) and
29 (33.7%) of 86 blood specimens from hepatocellular carci-
noma patients, respectively, while 45 specimens (52.3%) were
positive for at least one marker. In addition, MAGE-1,
MAGE-3 and AFP gene transcripts were not detected in any
peripheral blood specimens from 25 chronic liver disease
patients and 28 normal healthy volunteers [21].
El Aggan et al. also reported that, in HCC patients, the po-
sitive rate of MAGE-1 and MAGE-3 mRNA expression was
53.3% and 33.3% in peripheral blood samples respectively,
while the positive rate was 53.3% and 40% in HCC tissue sam-
ples, respectively. By contrast, MAGE-1 and MAGE-3 mRNA
were not detected in the adjacent non-neoplastic liver tissues or
in the peripheral blood samples of cirrhotic patients without
HCC and healthy subjects [22].
In this study the frequencies of the positive rate MAGE-1
and MAGE-3mRNAs in blood were associated with the pro-
gression of HCC as indicated by clinical parameters such asTNM tumor stage, tumor number and tumor size (p< 0.05)
but the correlation of AFP mRNA molecular marker with
the main HCC clinico-pathological parameters remains un-
clear; the positive rate of AFP mRNA when correlated with
TNM clinical stages, no correlation was found between tumor
number or tumor size.
Zhang et al., (2009) reported that the expression of MAGE-
1 mRNA and/or AFP mRNA in peripheral blood was closely
correlated with the pathological stage [23].
In contrast; Chen et al. [18] and Lupo et al. [24] found that
MAGE-1 genes are expressed in most HCC samples, but no
correlation was found with tumor size or stage of the disease;
the reason for this discrepancy may be due to the small number
of the tested patients.
The present study also demonstrated that although HCC
patients with a high level of serum AFP exhibited detectable
concentrations of MAGE-1, MAGE-3 and AFP mRNAs more
often than those with a low serum AFP level, there is no signif-
icant difference. The reason for the discrepancy among various
studies may be multifactorial. The limited number of tested pa-
tients and in the method of isolating circulating carcinoma
cells may be contributory factors.
Circulating hepatocytes positive for AFP mRNA have
rarely been reported in healthy persons [25–27]. In agreement
with the majority of other investigators [28–30], none of the
healthy controls included in the current study were positive
for circulating or MAGE-1, MAGE-3 and AFP mRNAs.
RT-PCR is a very sensitive technique for amplifying nucleic
acids [31,32], which could often be used to detect tiny amounts
of mRNA copies. Comparison of the sensitivities of RT-PCR
and nested RT-PCR revealed that nested RT-PCR provides
100 fold sensitivities. Moreover, the nested RT-PCR has in-
creased the speciﬁcity owing to the use of two pairs of speciﬁc
primers. Hence, nested RT-PCR is superior to RT-PCR with
respect to speciﬁcity and sensitivity for the detection of micro-
metastatic tumor cells.
Multimarker assay with cancer-speciﬁc MAGE-1 and
MAGE-3 mRNAs and liver speciﬁc AFP mRNA appears to
be a readily available and highly sensitive and speciﬁc method
for the detection of circulating HCC cells. Since nested PCR
utilizes a couple of internal primers to reamplify the speciﬁc
PCR product, it exhibits higher sensitivity, stronger speciﬁcity
and lower false-positive occurrence as compared to single RT.
Long-term follow-up of RT-PCR positive patients will be
required to determine its clinical relevance. If validated as a
predictor of early dissemination of cancer cells (metastatic po-
tential), this method would provide a powerful complement to
routine histopathologic analysis of HCC.
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